116355-84-1
Chemical Structure
Fumonisin B2
- CAS No.: 116355-84-1
- Formula:C34H59NO14
- Molecular Weight:705.83
IUPAC Name: (2R,2'R)-2,2'-((((5R,6R,7S,9S,16R,18S,19S)-19-amino-16,18-dihydroxy-5,9-dimethylicosane-6,7-diyl)bis(oxy))bis(2-oxoethane-2,1-diyl))disuccinic acid
InChIKey: UXDPXZQHTDAXOZ-STOIETHLSA-N
SMILES: OC(C[C@@H](C(O)=O)CC(O[C@@H](C[C@@H](C)CCCCCC[C@@H](O)C[C@H](O)[C@@H](N)C)[C@@H]([C@H](C)CCCC)OC(C[C@H](C(O)=O)CC(O)=O)=O)=O)=O
Biological Activity: Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fumonisin B2 | 99.99% | Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumonisin B2-13C34 | Fumonisin B2-13C34 is the 13C labeled Fumonisin B2 (HY-N6723). Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.95
HY-N6726RFumonisin B3 (Standard) -
Similarity Score 0.95
HY-N6726SFumonisin B3-13C34 -
Similarity Score 0.95
HY-N6726S1Fumonisin B3-13C34-1 -
Similarity Score 0.92
HY-N6719Fumonisin B1 -
Similarity Score 0.92
HY-N6719SFumonisin B1-13C34 -
Similarity Score 0.92
HY-N12329Fumonisin B4 -
Similarity Score 0.60
HY-N14062Halymecin E -
Similarity Score 0.60
HY-N6731Hydrolyzed Fumonisin B2 -
Similarity Score 0.59
HY-N14061Halymecin D -
Explore the MedChemAI to find more analogs
References
- [1]. Bondy GS, et al. A comparison of clinical, histopathological and cell-cycle markers in rats receiving the fungal toxins fumonisin B1 or fumonisin B2 by intraperitoneal injection. Food Chem Toxicol. 2000 Oct;38(10):873-86. [Content Brief]
- [2]. Yoo HS, et al. Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. Toxicol Appl Pharmacol. 1992 May;114(1):9-15. [Content Brief]
- [3]. Niderkorn V, et al. Cell wall component and mycotoxin moieties involved in the binding of fumonisin B1 and B2 by lactic acid bacteria. J Appl Microbiol. 2009 Mar;106(3):977-85. [Content Brief]
